HCPCS Level IIdrugActive
J9349
Inj., tafasitamab-cxix
BETOS: O1D
Effective: 2021-04-01
Description
Injection, tafasitamab-cxix, 2 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Monjuvi
Manufacturer
Incyte Corporation
HCPCS Dosage
2 MG
Billing Units
100.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.